Funding by Subsegment
Four of the seven Biotechnology subsegments exhibited growth in the first quarter of 2011 compared to the first quarter of 2010. Dollars invested in the Biotech Research, Biotech Industrial, Biotech Equipment, and Biotech Human subsegments rose 158 percent, 89 percent, 7 percent and 4 percent, respectively. The Human Biotechnology subsegment captured the largest share in the first quarter with $493 million going into 54 deals, a 4 percent increase in dollars and a 16 percent decrease in deals from Q1 of 2010.
Funding for two of the three Medical Device subsegments increased in Q1 2011, compared with the same quarter of 2010. The Medical Therapeutics category accounted for nearly two-thirds of the dollars and 62 percent of the deals during the first quarter with $391 million going into 49 deals. This represents a 26 percent increase in deals and a 30 percent increase in dollars compared to the first quarter of 2010.
Investments by Region
The top five metropolitan regions receiving Life Sciences venture capital funding during Q1 2011 were San Francisco Bay ($381 million), New York Metro ($190 million), Boston ($182 million), San Diego Metro ($82 million), and North Carolina Research Triangle ($68 million). Investments in Biotechnology deals accounted for 76 percent of the dollars invested in the top five regions in Q1 2011.
Three of the top regions experienced increases in funding on a year-over-year basis during the first quarter of 2011. New York Metro received $93 million more venture capital funding than the same period of the previous year, and the region recorded the highest year-over-year increase among metropolitan regions.
A full copy of the report is available for download at www.pwc.com/us/lifesciencesmoneytree
About PwC's Pharmaceutical and Life Sciences Industry Group<
Copyright©2010 PR Newswire.
All rights reserved